Skip To Content

Study ID: GOG 0213


Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer

Standard treatment for recurrent ovarian, primary peritoneal, or fallopian tube cancer usually consists of two chemotherapy drugs, carboplatin and paclitaxel, which are given every three weeks for a total of six treatments. Chemotherapy is given to control the growth of your cancer and to lower the chance of it coming back. One purpose of this study is to compare the combination of carboplatin, paclitaxel and bevacizumab to the standard combination of carboplatin and paclitaxel alone. A second purpose of this study is to determine if a second surgery to remove tumor followed by chemotherapy can increase the time that patients remain disease free. If a doctor feels that a patient is a good candidate for the second surgery that patient will be randomized to have surgery or not and at the same time will be randomized to receive one of the two possible chemotherapy combinations.
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Maria Bell, MD
Ovary/Fallopian Tube/Primary Peritoneal
Phase III
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.